- Gilead Sciences, the company that makes the antiviral drug remdesivir, announced on Monday that it is about to start trials of an inhaled version of the medication.
"After receiving the green light from the FDA to move forward, Gilead is about to start trials of an inhaled version of remdesivir. We will screen healthy volunteers for Phase 1 trials this week and hope to begin studies in patients with COVID-19 in August," Daniel O'Day, Gilead Sciences chairman and CEO, said in an open letter on Monday.
The letter went on to explain how there are also plans to study remdesivir in treating COVID-19 earlier in the progression of the disease, in combination with other therapies and in additional patient groups. Last week, Gilead announced it would begin advanced trials of the drug in children.